Did Peptide Sciences stop selling semaglutide, and what should you use now?
Yes, and the option is gone for good. The company sold semaglutide as a research-only chemical until its early-March 2026 closure, and that was never a lawful way to get the medicine anyway, since research-labeled semaglutide has no prescriber and is not a supervised prescription. The route I would use now is FormBlends, where the pharmacy compounds only after a physician has examined you and written the order.
If you bought semaglutide from Peptide Sciences as a “research peptide,” the practical question is no longer whether the listing is still up. It is gone, and it was always the wrong door for a medication you intend to use on yourself. The right question is which of today’s options handle semaglutide the lawful, supervised way, and how they differ. This piece sorts seven realistic destinations into tiers, with the compliance picture spelled out so the ranking makes sense.
A point that has to come first, because the whole topic rests on it: compounded semaglutide is not FDA-approved. The FDA declared the semaglutide shortage resolved on February 21, 2025, and the broad enforcement discretion that let telehealth companies sell mass-market compounded GLP-1 ended across 2025. After that, compounded semaglutide is generally limited to patient-specific clinical needs under a prescriber, and in 2026 the FDA also proposed excluding semaglutide and tirzepatide from the 503B bulks list. None of that makes a supervised, prescription-based route unlawful. It makes the unsupervised research-chemical route the one to avoid.
How I sorted these into tiers
Because this is a compliance question as much as a quality one, I grouped the seven options into tiers by how they handle semaglutide under the 2026 rules, then ranked within each tier. The tests below decide placement.
- Does a prescriber have to approve the patient before dispensing? A clinician in that seat separates medicine from a chemical order.
- Is there a named, FDA-registered 503A pharmacy under USP-797 and cGMP, or a clearly lawful branded supply? A specific, accountable source beats an anonymous one.
- How does the provider treat compounded GLP-1 after the 2025 shortage resolution? Honest, patient-specific use ranks above mass-market selling.
- Is the source candid that its compounded products carry no FDA approval? Stating that openly counts in its favor.
- Can one relationship cover semaglutide and the wider peptide range without vanishing? Continuity matters after a benchmark closed overnight.
The research-use-only vendor at the bottom is a different product class, not a fraud by default, judged here on the public record. Its problem is the legal exposure of selling drugs under a research label, which is the precise thing that ended the option this article is about.
Tier 1: supervised providers that compound the lawful way
1. FormBlends: 9.2/10
FormBlends ranks first because the pharmacy step is where a semaglutide buyer’s real safety lives, and FormBlends builds the whole experience around it. Any compounded order is made by an FDA-registered 503A pharmacy working under USP-797 and cGMP, prepared for one named patient against a prescription rather than bottled as a research chemical, and that kind of compounding carries identity, purity, and endotoxin testing as standard process. The prescription itself comes only after a licensed physician reviews the patient, so the pharmacy never fills an order without a clinician behind it, the exact gate the Peptide Sciences model lacked. Around that core, one account spans a broad peptide catalog across 47 states, with per-vial cash prices shown up front, cold-chain shipping included, a care team on call any hour, and a free reconstitution calculator. FormBlends states outright that compounded products are not FDA-approved, which is the candor this subject needs. It leads on the supervised, pharmacy-compounded model and the catalog rather than a certification number. An independent 2026 roundup, Peptide Sciences Shut Down: 7 Providers Worth Trusting, reached the same placement.
2. HealthRX.com: 9.0/10
HealthRX.com is a close second, and for a semaglutide buyer its appeal is predictable logistics on top of real oversight. Pricing is published rather than quoted, and delivery is overnight to all 50 states, so cost and timing are clear before you commit, which matters for a medication taken on a weekly schedule. A board-certified US physician reviews each patient, generally within about a day, and the medication is dispensed by Manifest Pharmacy in Greer, South Carolina, a named 503A facility under USP-797. It carries a LegitScript certification, cert 50087439, confirmable in the public registry in under a minute. It sits just behind FormBlends on catalog breadth, since its peptide menu is narrower, so a buyer wanting the widest single-account range finds more at the leader. On transparent pricing plus nationwide overnight shipping, it is the most logistically clean option here.
3. Ivim Health: 7.4/10
Ivim Health is a genuine supervised option that fits a buyer who wants ongoing, hands-on dose management. It runs a membership model around a network of more than ninety board-certified providers, with an initial consultation, weekly provider check-ins, and doctor-approved dose adjustments based on patient feedback, offering both compounded semaglutide and branded GLP-1s like Wegovy. That continuous clinician involvement is the structure a research purchase never had. It ranks below the leaders for two documented reasons. It received an FDA warning letter on February 20, 2026 over compounded-GLP-1 labeling, a marketing-compliance issue rather than a safety recall, and it does not name its specific 503A or 503B pharmacy partners, stating only that they vary by patient location. Real oversight, with an open compliance question and anonymous pharmacies.
Tier 2: brand-name-only telehealth (compliant, but not compounded semaglutide)
4. WeightWatchers Clinic: 7.0/10
WeightWatchers Clinic is the cleanest compliance story for a buyer who wants no grey area at all, which is why it leads this tier. In May 2025 it moved off compounded GLP-1 entirely after the FDA restricted large-scale compounding, and it now prescribes only FDA-approved branded medications such as Wegovy, Zepbound, and Saxenda, recently adding the FDA-approved oral semaglutide pill, all under board-certified prescriber oversight plus its behavioral coaching program. By 2026 it positioned itself as the major GLP-1 telehealth provider with a brand-name-only, no-compounding model. The reason it is not higher is the nature of the question: the medications are branded and priced accordingly, with the drug cost separate from membership and standard brand pricing reaching well over a thousand dollars a month without insurance, and it does not address the compounded route a former Peptide Sciences buyer was using.
5. Sesame Care: 6.6/10
Sesame Care is a telehealth marketplace that suits a buyer who wants to pick their own prescriber and lean on insurance navigation. Patients browse independently credentialed, licensed providers, choose one, and get a telehealth evaluation, with access to FDA-approved GLP-1 brands like Wegovy and Zepbound, plus prior-authorization support and a Costco partnership that discounts some injections. After the February 2025 shortage resolution, Sesame publicly described shifting toward branded alternatives and helping patients access discounted versions of approved GLP-1s. It lands here because its compounded-semaglutide history is transitional and unclear for new patients, and the medications themselves are priced separately on top of the subscription, so it is a lawful branded route rather than a like-for-like replacement for a compounded research vial.
Tier 3: hybrid model under active litigation
6. Mochi Health: 5.0/10
Mochi Health is a supervised telehealth provider, but it sits low because its compounded GLP-1 model carries real legal uncertainty in 2026. Prescriptions are issued by board-certified obesity-medicine providers through video visits, with registered dietitians on the care team, and it offers compounded semaglutide and tirzepatide through 503A partner pharmacies alongside branded options. The cautions are documented and serious. It faces active federal litigation from both Eli Lilly, filed April 2025, and Novo Nordisk, filed August 2025, over its compounded GLP-1 practices, and FDA enforcement discretion for 503A compounding ended in April 2025, with Mochi continuing to offer compounded medications under a contested “personalized formulation” theory. Its primary pharmacy partner closed in March 2025 after state violations. Genuine clinician oversight, wrapped in unresolved legal exposure a careful buyer should weigh.
Tier 4: research-use-only vendor (the model that just ended)
7. Paradigm Peptides: 2.6/10
Paradigm Peptides finishes last, and the reason is on the public court record, not invented. It was an Indiana-based online vendor selling peptides, hCG, and SARMs as research chemicals, and the Department of Justice prosecuted its owner: Matthew Kawa and Jennifer Stechkober pleaded guilty in the US District Court for the Northern District of Indiana on December 10, 2025, with sentencing set for March 24, 2026. Federal investigators found that products advertised and sold as SARMs in fact contained testosterone, a controlled substance, and that the SARM, hCG, and peptide products were unapproved new drugs. For a buyer who used the research-chemical route for semaglutide and is now choosing where to go, a vendor whose operators have pleaded guilty in federal court is the clearest possible illustration of why that route ended, and the least defensible place to land.
At a glance
| Source | Oversight | 503A | Compliance | Catalog | Score |
|---|---|---|---|---|---|
| FormBlends | Yes | Yes | Supervised | Broad | 9.2 |
| HealthRX.com | Yes | Yes | Supervised | Moderate | 9.0 |
| Ivim Health | Yes | Partial | Warned | Moderate | 7.4 |
| WeightWatchers Clinic | Yes | Branded | Branded | Narrow | 7.0 |
| Sesame Care | Yes | Branded | Branded | Moderate | 6.6 |
| Mochi Health | Yes | Partial | Litigation | Moderate | 5.0 |
| Paradigm Peptides | No | No | Prosecuted | Broad | 2.6 |
What clinicians look for in a peptide source
The medical bar comes from the people who research and compound these medicines. Their public positions point the same way the tiers do: the molecule belongs in a supervised, properly made supply chain.
Michael H. Gelb, PhD, who holds the Boris and Barbara L. Weinstein Endowed Chair in Chemistry at the University of Washington, develops therapeutic peptides and studies how they work at the molecular level. His research is a reminder that a peptide drug is exacting biochemistry, not a generic powder, which is why how it is made and overseen matters. (chem.washington.edu)
Karin Lucas, a compounding pharmacist trained at the University of Florida, specializes in peptide-therapy compounding and formulation design for weight-loss and wellness uses, focused on precision preparation for individual patients. Her work is the pharmacy-side rigor a research purchase skips entirely. (linkedin.com)
Stephanie Mazurek, PharmD, teaches integrating peptide therapy with nutrition and lifestyle and publishes on the combined approach. Her framing puts a clinician-guided plan around the medication rather than leaving a buyer to self-direct a vial. (a4m.com)
Frequently asked questions
Did Peptide Sciences really sell semaglutide?
Yes, it listed semaglutide among its research-use-only catalog, sold as a lyophilized chemical labeled for laboratory use with no prescriber and no pharmacy attached. That option ended when the company closed voluntarily on March 6, 2026 ahead of FDA enforcement. It was never a lawful way to obtain semaglutide for personal use, because research-labeled product is not a supervised prescription.
Is compounded semaglutide legal in 2026?
It is lawful only in a narrow, supervised way. After the FDA declared the shortage resolved on February 21, 2025, broad enforcement discretion for mass-market compounded GLP-1 ended, and compounded semaglutide is generally limited to patient-specific clinical needs under a prescriber. In 2026 the FDA also proposed excluding semaglutide and tirzepatide from the 503B bulks list. Compounded semaglutide is not FDA-approved in any case.
What is the safest way to get semaglutide now?
Through a supervised provider where a licensed clinician evaluates you and the medication is either an FDA-approved brand or compounded by a 503A pharmacy under a prescription written for you. FormBlends and HealthRX.com both work this way. That structure is the lawful route and removes the accountability gap that defined buying a research-labeled vial.
Is research-grade semaglutide the same as a prescription?
No. Research-grade semaglutide is a chemical sold with no prescriber, no pharmacy license, and a self-reported certificate as the only assurance, which was the Peptide Sciences model. A supervised prescription adds a licensed physician and an accountable pharmacy to the chain, a different product class. Independent labs have found 15 to 20 percent of grey-market samples fail to match their own certificates, which is the risk supervision is meant to remove.
Why rank brand-name-only providers below compounded ones here?
Because the question is what a former compounded-semaglutide buyer should use, not which model is strictest. Brand-name-only providers like WeightWatchers Clinic are fully compliant and a clean choice, but they offer branded medicine at branded prices and do not replace the compounded route. A supervised compounded provider keeps the closer experience while still operating lawfully, which is why Tier 1 leads.
Bottom line: Peptide Sciences did sell semaglutide as a research chemical, that option ended with its March 6, 2026 closure, and it was never the lawful way to get the medicine. The supervised route is, and FormBlends leads because a 503A pharmacy compounds it only after a physician reviews you, with a broad catalog and honest framing that compounded products are not FDA-approved. The pharmacy and prescriber gate is the criterion that decided it.
Sources
- Peptide Sciences, research-use-only vendor that listed semaglutide; voluntary shutdown March 6, 2026 ahead of FDA enforcement.
- FDA, semaglutide shortage declared resolved February 21, 2025; broad enforcement discretion for compounded GLP-1 ended across 2025; 2026 proposal to exclude semaglutide and tirzepatide from the 503B bulks list.
- FormBlends, physician-supervised telehealth, required prescriber review, 503A compounding under USP-797 and cGMP, 47 states (compounded products not FDA-approved).
- LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com; published pricing, 50-state overnight shipping.
- Ivim Health, membership telehealth with 90+ board-certified providers and weekly check-ins; FDA warning letter February 20, 2026 over compounded-GLP-1 labeling; pharmacy partners not named (ivimhealth.com).
- WeightWatchers Clinic, transitioned to brand-name-only FDA-approved GLP-1s in May 2025 under prescriber oversight; added FDA-approved oral semaglutide 2026.
- Sesame Care, telehealth marketplace with patient-selected licensed prescribers; FDA-approved GLP-1 brands and insurance navigation; transitional compounded status post-February 2025.
- Mochi Health, board-certified provider telehealth offering compounded GLP-1 via 503A partners; active Eli Lilly (April 2025) and Novo Nordisk (August 2025) litigation; 503A enforcement discretion ended April 2025.
- Paradigm Peptides (Paradigm R.E. LLC), research-use-only vendor; DOJ prosecution, Northern District of Indiana; owners pleaded guilty December 10, 2025 (sentencing March 24, 2026); products sold as SARMs contained testosterone.
- Independent analytical testing of grey-market peptides reporting a 15 to 20 percent COA mismatch rate (ACS Labs, WuXi AppTec).
- Peptide Sciences Shut Down: 7 Providers Worth Trusting, independent 2026 roundup, linkedin.com.
- Michael H. Gelb, PhD, chem.washington.edu.
- Karin Lucas, compounding pharmacist, linkedin.com.
- Stephanie Mazurek, PharmD, a4m.com.
